OBSV - ObsEva SA

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
16.70
+0.21 (+1.27%)
As of 3:14PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close16.49
Open16.64
Bid16.74 x 800
Ask16.79 x 800
Day's Range16.23 - 17.21
52 Week Range7.09 - 20.35
Volume186,033
Avg. Volume131,907
Market Cap759.028M
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)-2.09
Earnings DateAug 13, 2018 - Aug 17, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est31.00
Trade prices are not sourced from all markets
  • Barrons.com4 days ago

    ObsEva: A Small Biotech With a Promising Pipeline

    Geneva-based ObsEva has three drugs designed to aid women’s reproductive health nearing the regulatory approval stage.

  • Can the Rally in ObsEva (OBSV) Shares Continue?
    Zacks4 days ago

    Can the Rally in ObsEva (OBSV) Shares Continue?

    ObsEva SA (OBSV) has been on the move lately as the stock has risen by 22.7% in the past four weeks, and it is currently trading well above its 20-Day SMA.

  • Is ObsEva SA (NASDAQ:OBSV) A Healthcare Leader?
    Simply Wall St.6 days ago

    Is ObsEva SA (NASDAQ:OBSV) A Healthcare Leader?

    ObsEva SA (NASDAQ:OBSV), a US$651.8m small-cap, is a healthcare company operating in an industry, which continues to endure a more demanding healthcare agenda, and the global need for innovative, cost-effectiveRead More...

  • GlobeNewswire22 days ago

    ObsEva SA to Participate in September Investor Conferences

    Geneva, Switzerland and Boston, MA– August 28, 2018- ObsEva SA, a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions ...

  • Thomson Reuters StreetEvents27 days ago

    Edited Transcript of OBSV.O earnings conference call or presentation 8-Aug-18 12:00pm GMT

    Q2 2018 Obseva SA Earnings Call

  • GlobeNewswire28 days ago

    New Research: Key Drivers of Growth for ObsEva SA, Gran Tierra Energy, Constellium N.V, Just Energy Group, Hovnanian Enterprises, and First Majestic Silver — Factors of Influence, Major Initiatives and Sustained Production

    NEW YORK, Aug. 21, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ObsEva ...

  • GlobeNewswirelast month

    ObsEva SA to Participate in Wedbush PacGrow Healthcare Conference August 14-15, 2018

    Geneva, Switzerland and Boston, MA- August 10, 2018- ObsEva SA, a Swiss clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions ...

  • ObsEva SA (OBSV) Reports Q2 Loss, Misses Revenue Estimates
    Zackslast month

    ObsEva SA (OBSV) Reports Q2 Loss, Misses Revenue Estimates

    ObsEva SA (OBSV) delivered earnings and revenue surprises of 9.26% and -100.00%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

  • ACCESSWIRElast month

    ObsEva SA to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 8, 2018 / ObsEva SA (NASDAQ: OBSV ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 8, 2018 at 8:00 AM Eastern Time. To listen ...

  • GlobeNewswirelast month

    ObsEva Reports Second Quarter 2018 Financial Results and Provides Business Update

    Phase 2 b EDELWEISS clinical trial of linzagolix in endometriosis related pelvic pain achieved primary and secondary endpoints Chief Commercial Officer hired as nolasiban moves closer to commercialization ...

  • ObsEva SA (OBSV) Sees Hammer Chart Pattern: Time to Buy?
    Zacks2 months ago

    ObsEva SA (OBSV) Sees Hammer Chart Pattern: Time to Buy?

    ObsEva has been struggling lately, but the selling pressure may be coming to an end soon.

  • GlobeNewswire2 months ago

    ObsEva SA to Hold Second Quarter 2018 Financial Results and Business Update Call on August 8, 2018

    Geneva, Switzerland and Boston, MA - July 31, 2018 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics ...

  • GlobeNewswire2 months ago

    ObsEva SA to Hold Second Quarter 2018 Financial Results and Business Update Call on August 8, 2018

    Geneva, Switzerland and Boston, MA- July 31, 2018- ObsEva SA, a Swiss clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions ...

  • GlobeNewswire2 months ago

    ObsEva Expands Executive Team Hiring a Chief Commercial Officer

    July 25, 2018 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman`s reproductive health and pregnancy, today announced the appointment of a Chief Commercial Officer, Wim Souverijns, who will be based at the Company headquarters in Geneva, Switzerland. Mr. Souverijns brings nearly 20 years of experience in the pharmaceutical industry and recently served as Corporate Vice President, Global Marketing, Hematology & Oncology within Celgene out of Summit, New Jersey.

  • GlobeNewswire2 months ago

    ObsEva Expands Executive Team Hiring a Chief Commercial Officer

    July 25, 2018 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy, today announced the appointment of a Chief Commercial Officer, Wim Souverijns, who will be based at the Company headquarters in Geneva, Switzerland. Mr. Souverijns brings nearly 20 years of experience in the pharmaceutical industry and recently served as Corporate Vice President, Global Marketing, Hematology & Oncology within Celgene out of Summit, New Jersey.

  • GlobeNewswire2 months ago

    ObsEva SA to start trading today on the SIX Swiss Exchange

    July 13, 2018 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman`s reproductive health and pregnancy, announced that its shares will be listed and start trading today under the "International Reporting Standard" on SIX Swiss Exchange. The issued share capital comprises 45`381`252 registered shares with a nominal value of 1/13 of CHF 1 each.

  • GlobeNewswire2 months ago

    ObsEva SA to start trading today on the SIX Swiss Exchange

    July 13, 2018 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy, announced that its shares will be listed and start trading today under the "International Reporting Standard" on SIX Swiss Exchange. The issued share capital comprises 45'381'252 registered shares with a nominal value of 1/13 of CHF 1 each.

  • Reuters2 months ago

    ObsEva plans Swiss listing; trading debut on July 13

    ObsEva, a Switzerland-based drug development company, said on Friday it plans a secondary listing on the SIX Swiss Exchange in Zurich and trading debut on July 13, as the firm seeks to gain more visibility among European investors. Geneva-based ObsEva, founded by gynaecologist and former Serono drug developer Ernest Loumaye, started trading on the Nasdaq in 2017 and has a market capitalisation of about $658 million. ObsEva, which will trade under the ticker symbol "OBSN.S", will not issue any new shares in connection with the Swiss listing.

  • GlobeNewswire2 months ago

    ObsEva SA Shares to Begin Trading on SIX Swiss Exchange

    ObsEva has a unique pipeline of novel and potential best-in class therapeutics to address serious conditions with a high unmet medical need affecting millions of women. Geneva, Switzerland and Boston, MA - July 6, 2018 - ObsEva SA (OBSV), a Swiss clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy, today announced the listing of its shares on SIX Swiss Exchange with the publication of its listing prospectus.

  • GlobeNewswire2 months ago

    ObsEva SA Shares to Begin Trading on SIX Swiss Exchange

    ObsEva has a unique pipeline of novel and potential best-in class therapeutics to address serious conditions with a high unmet medical need affecting millions of women. Geneva, Switzerland and Boston, MA - July 6, 2018 - ObsEva SA (OBSV), a Swiss clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman`s reproductive health and pregnancy, today announced the listing of its shares on SIX Swiss Exchange with the publication of its listing prospectus.

  • GlobeNewswire3 months ago

    ObsEva Announces Pricing of Follow-on Public Offering

    June 20, 2018 - ObsEva SA (OBSV), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman`s reproductive health and pregnancy, announced today the pricing of an underwritten public offering of 4,750,000 common shares at a price of $15.39 per share, before underwriting discounts and commissions. In addition, ObsEva has granted the underwriters a 30-day option to purchase up to an additional 712,500 common shares at the public offering price, less the underwriting discounts and commissions. ObsEva anticipates the total gross proceeds from the offering (before deducting the underwriting discounts and commission and estimated offering expenses) will be $73.1 million, excluding any exercise of the underwriters` option to purchase additional shares.  ObsEva intends to use the net proceeds from the proposed offering primarily to continue the development of its three new chemical entities in its pipeline and invest in pre-commercial activates in support of its pipeline assets, and for working capital and other general corporate purposes.

  • GlobeNewswire3 months ago

    ObsEva Announces Launch of Proposed Follow-on Public Offering

    June 18, 2018 - ObsEva SA (OBSV), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman`s reproductive health and pregnancy, announced today the launch of a proposed underwritten public offering of 4,750,000 common shares. ObsEva intends to use the net proceeds from the proposed offering primarily to continue the development of its three new chemical entities in its pipeline and invest in pre-commercial activates in support of its pipeline assets, and for working capital and other general corporate purposes. J.P. Morgan Securities LLC, Credit Suisse Securities (USA) LLC and Jefferies LLC are acting as joint bookrunning managers.

  • GlobeNewswire3 months ago

    ObsEva SA Achieves Primary and Secondary Endpoints for EDELWEISS Phase 2b Clinical Trial of Linzagolix (OBE2109) in Women with Endometriosis

    Partial suppression of estradiol with moderate dose (75mg) of linzagolix demonstrated highly significant reduction of pain and improvement of patient well-being High dose (200mg) of linzagolix achieves ...